EA200401478A1 - Монооксид углерода в качестве биомаркера и лекарственного средства - Google Patents
Монооксид углерода в качестве биомаркера и лекарственного средстваInfo
- Publication number
- EA200401478A1 EA200401478A1 EA200401478A EA200401478A EA200401478A1 EA 200401478 A1 EA200401478 A1 EA 200401478A1 EA 200401478 A EA200401478 A EA 200401478A EA 200401478 A EA200401478 A EA 200401478A EA 200401478 A1 EA200401478 A1 EA 200401478A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- lung
- diseases
- biomarker
- carbon monoxide
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Настоящее изобретение относится к использованию монооксида углерода (CO) в качестве биомаркера и лекарственного средства при лечении болезней сердца, легкого, печени, селезенки, головного мозга, кожи и почки и других состояний, а также болезненных состояний, включающих, например, астму, эмфизему, бронхит, респираторный дистресс-синдром взрослых, сепсис, муковисцидоз, пневмонию, интерстициальные болезни легких, идиопатические заболевания легких, другие заболевания легких, включая первичную легочную гипертензию, вторичную легочную гипертензию, рак, в том числе рак легкого, гортани и горла, артрит, заживление ран, болезнь Паркинсона, болезнь Альцгеймера, периферическое заболевание сосудов и тромботические заболевания сосудов легких, такие как эмболия сосудов легких. CO может применяться для того, чтобы за счет ослабления воспаления вызвать облегчение у пациентов, страдающих от окислительного стресса и других состояний, в особенности сепсиса и септического шока. Кроме того, монооксид углерода может применяться в качестве биомаркера или лекарственного средства с целью снижения респираторного нарушения у пациентов, которым проводилась трансплантация легкого, и с целью снижения или подавления окислительного стресса и воспаления у пациентов, которым проводилась трансплантация.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2002/014836 WO2003094932A1 (en) | 2002-05-09 | 2002-05-09 | Carbon monoxide as a biomarker and therapeutic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200401478A1 true EA200401478A1 (ru) | 2005-12-29 |
Family
ID=29418043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200401478A EA200401478A1 (ru) | 2002-05-09 | 2002-05-09 | Монооксид углерода в качестве биомаркера и лекарственного средства |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1501523A4 (ru) |
| JP (1) | JP2005532314A (ru) |
| KR (1) | KR20040106515A (ru) |
| CN (1) | CN1638781A (ru) |
| AU (1) | AU2002308676B2 (ru) |
| BR (1) | BR0215717A (ru) |
| CA (1) | CA2484770A1 (ru) |
| EA (1) | EA200401478A1 (ru) |
| MX (1) | MXPA04011113A (ru) |
| NO (1) | NO20044865L (ru) |
| RS (1) | RS96904A (ru) |
| UA (1) | UA84402C2 (ru) |
| WO (1) | WO2003094932A1 (ru) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7678390B2 (en) | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
| GB0111872D0 (en) | 2001-05-15 | 2001-07-04 | Northwick Park Inst For Medica | Therapeutic agents and methods |
| AU2003208525B9 (en) | 2002-02-04 | 2009-08-27 | Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda | Amend the invention title to read Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof |
| MXPA04010243A (es) | 2002-04-15 | 2005-07-05 | Univ Pittsburgh | Metodos para tratar ileo. |
| EP1499328B1 (en) | 2002-04-15 | 2015-09-16 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Methods of treating necrotizing enterocolitis |
| WO2003096977A2 (en) * | 2002-05-17 | 2003-11-27 | Yale University | Methods of treating hepatitis |
| JP2005345242A (ja) * | 2004-06-02 | 2005-12-15 | Tohoku Univ | 肺癌の化学療法治療効果の評価方法 |
| JPWO2007073005A1 (ja) * | 2005-12-22 | 2009-06-04 | 学校法人慶應義塾 | メチル基転移反応調節物質 |
| EP2099439A2 (en) * | 2006-12-06 | 2009-09-16 | Alfama - Investigação E Desenvolvimento De Produto | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof |
| JP2010094122A (ja) | 2008-06-12 | 2010-04-30 | Keio Gijuku | バイオマーカーとしてのマイクロｒｎａを用いた頭頸部腫瘍の診断・治療選択 |
| JP2012046470A (ja) * | 2010-08-30 | 2012-03-08 | Japan Science & Technology Agency | Ｇａｐｄｈの酵素活性阻害剤 |
| CA2824056C (en) * | 2011-01-14 | 2019-01-08 | Children's Hospital Los Angeles | Solution of carbon monoxide for treatment of disease, including sickle cell disease |
| US8927750B2 (en) | 2011-02-04 | 2015-01-06 | Universitaet Zu Koeln | Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules |
| US9359197B2 (en) | 2011-03-24 | 2016-06-07 | Technion Research & Development Foundation Ltd. | Method of diagnosing, prognosing and monitoring parkinson's disease |
| EP2699242B1 (en) | 2011-04-19 | 2017-11-01 | Alfama, Inc. | Carbon monoxide releasing molecules and uses thereof |
| EP2734235B1 (en) | 2011-07-21 | 2017-03-22 | Alfama, Inc. | Ruthenium carbon monoxide releasing molecules and uses thereof |
| US10031126B2 (en) | 2013-04-04 | 2018-07-24 | The Regents Of The University Of California | System and method for utilizing exhaled breath for monitoring inflammatory states |
| EP2868348A1 (en) * | 2013-11-04 | 2015-05-06 | Universität Zürich | CO-releasing compounds & formulations thereof useful for inducing mitochondrial biogenesis and tissue repair |
| TW201618795A (zh) * | 2014-04-15 | 2016-06-01 | 波泰里斯股份有限公司 | 用以改良器官功能及延長器官移植物壽命之系統及方法 |
| JP7161737B2 (ja) * | 2017-01-30 | 2022-10-27 | 哲也 石川 | 悪性腫瘍の検査方法 |
| CN112236150A (zh) | 2018-06-08 | 2021-01-15 | 住友精化株式会社 | 炎症性消化器官疾病用组合物 |
| US20210228621A1 (en) * | 2018-06-08 | 2021-07-29 | Sumitomo Seika Chemicals Co., Ltd. | Composition for skin wounds |
| US20220296636A1 (en) * | 2019-06-06 | 2022-09-22 | The General Hospital Corporation | Carbon Monoxide as a Treatment for Neurodegenerative Disease |
| US20230346831A1 (en) * | 2020-07-16 | 2023-11-02 | Cornell University | Methods for treating metastatic cancer using low dose carbon monoxide |
| US11636870B2 (en) | 2020-08-20 | 2023-04-25 | Denso International America, Inc. | Smoking cessation systems and methods |
| US11828210B2 (en) | 2020-08-20 | 2023-11-28 | Denso International America, Inc. | Diagnostic systems and methods of vehicles using olfaction |
| US11760169B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Particulate control systems and methods for olfaction sensors |
| US11932080B2 (en) | 2020-08-20 | 2024-03-19 | Denso International America, Inc. | Diagnostic and recirculation control systems and methods |
| US11760170B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Olfaction sensor preservation systems and methods |
| US11813926B2 (en) | 2020-08-20 | 2023-11-14 | Denso International America, Inc. | Binding agent and olfaction sensor |
| US12017506B2 (en) | 2020-08-20 | 2024-06-25 | Denso International America, Inc. | Passenger cabin air control systems and methods |
| US11881093B2 (en) | 2020-08-20 | 2024-01-23 | Denso International America, Inc. | Systems and methods for identifying smoking in vehicles |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5293875A (en) * | 1992-06-16 | 1994-03-15 | Natus Medical Incorporated | In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods |
| DE4421433C1 (de) * | 1994-06-18 | 1995-06-08 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung |
| JP2000517311A (ja) * | 1996-08-27 | 2000-12-26 | メッサー グリースハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング | 水素含有薬剤 |
| MXPA03008820A (es) * | 2001-03-30 | 2004-07-30 | Sangstat Medical Corp | Compuestos generadores de monoxido de carbono, para el tratamiento de desordenes vasculares, inflamatorios e inmunologicos. |
-
2002
- 2002-05-09 WO PCT/US2002/014836 patent/WO2003094932A1/en active Application Filing
- 2002-05-09 MX MXPA04011113A patent/MXPA04011113A/es active IP Right Grant
- 2002-05-09 CN CNA028292995A patent/CN1638781A/zh active Pending
- 2002-05-09 AU AU2002308676A patent/AU2002308676B2/en not_active Ceased
- 2002-05-09 KR KR10-2004-7018082A patent/KR20040106515A/ko not_active Application Discontinuation
- 2002-05-09 UA UA20041210106A patent/UA84402C2/ru unknown
- 2002-05-09 CA CA002484770A patent/CA2484770A1/en not_active Abandoned
- 2002-05-09 EP EP02807413A patent/EP1501523A4/en not_active Withdrawn
- 2002-05-09 EA EA200401478A patent/EA200401478A1/ru unknown
- 2002-05-09 JP JP2004503016A patent/JP2005532314A/ja active Pending
- 2002-05-09 RS YUP-969/04A patent/RS96904A/sr unknown
- 2002-05-09 BR BR0215717-9A patent/BR0215717A/pt not_active Application Discontinuation
-
2004
- 2004-11-09 NO NO20044865A patent/NO20044865L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04011113A (es) | 2005-02-14 |
| AU2002308676A1 (en) | 2003-11-11 |
| KR20040106515A (ko) | 2004-12-17 |
| WO2003094932A1 (en) | 2003-11-20 |
| EP1501523A4 (en) | 2006-12-13 |
| UA84402C2 (ru) | 2008-10-27 |
| AU2002308676B2 (en) | 2009-06-11 |
| BR0215717A (pt) | 2005-02-22 |
| EP1501523A1 (en) | 2005-02-02 |
| CN1638781A (zh) | 2005-07-13 |
| CA2484770A1 (en) | 2003-11-20 |
| NO20044865L (no) | 2004-12-07 |
| JP2005532314A (ja) | 2005-10-27 |
| RS96904A (en) | 2007-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200401478A1 (ru) | Монооксид углерода в качестве биомаркера и лекарственного средства | |
| Nayyar et al. | Defining and characterizing severe hypoxemia after liver transplantation in hepatopulmonary syndrome | |
| Wong et al. | Post-tonsillectomy infiltration with bupivacaine reduces immediate postoperative pain in children | |
| SE0200356D0 (sv) | Novel use | |
| EA200500782A1 (ru) | Лечение геморрагического шока | |
| NO20052987L (no) | Forbindelser for normalisering av sovn/vaken-syklusen. | |
| ATE296056T1 (de) | Atemfunktionsanalyse mittels kapnographie | |
| EA199800690A1 (ru) | Замещенные n-[(аминоиминометил)фенилалкил]азагетероцикламиды сульфоновых кислот | |
| MX2023002522A (es) | Compuestos novedosos para usar en el tratamiento de enfermedades asociadas con la angiotensina ii. | |
| Sahin et al. | The effect of hyperbaric oxygen therapy on erectile functions: a prospective clinical study | |
| EA200001192A1 (ru) | Каберголин и прамипексол для лечения заболевания цнс, особенно болезни паркинсона | |
| RU2010100484A (ru) | Новые соединения 892 | |
| Holman et al. | Surgical treatment of H-type tracheoesophageal fistula diagnosed in an adult | |
| Lemko et al. | The usage of haloaerosoltherapy in the rehabilitational treatment of children with reccurent bronchitis | |
| RU2005115102A (ru) | Новые противоопухолевые соединения | |
| 조상호 et al. | Heart rate change while drowsy driving | |
| Sadighi et al. | Effect of diabetes mellitus type II on long bones fractures healing | |
| Lavery et al. | Does the choice of the neuromuscular blocking agent affect the cardiovascular response to intubation? | |
| Dunn | Fractured Olecranon | |
| Lipford et al. | 0587 Demographic Characteristics and Comorbidities of Patients With Narcolepsy: A Propensity Score–Matched Cohort Study | |
| RU2464007C1 (ru) | Способ лечения больных хронической обструктивной болезнью легких | |
| Maggini et al. | Psychological and physiopathological study on coronary patients | |
| Kotel’nikov et al. | Autonomic Cardiac Regulation in Experimental Comorbidity of Chronic Obstructive Pulmonary Disease and Acute Cerebral Ischemia | |
| Yamamoto et al. | Combined pulmonary fibrosis and emphysema with rheumatoid arthritis | |
| RU2142768C1 (ru) | Способ лечения пневмокониозов |